Global Biotechnology Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2019 – ResearchAndMarkets.com
Global Biotechnology Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2019 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Licensing Deals in Biotechnology 2019-2024” report has been added to ResearchAndMarkets.com’s offering.
Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully revised and updated, the report provides details of licensing deals from 2019 to 2024.
The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of licensing dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in licensing as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of licensing deals.
Chapter 4 provides a review of the leading licensing deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active licensing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the licensing deal.
The deal directory includes a comprehensive listing of all licensing deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2019.
In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.
Key Benefits
- Understand deal trends since 2019
- Browse licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms – upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents – insights into deal structures
- Due diligence – assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Licensing Deals in Biotechnology includes:
- Trends in licensing dealmaking in the biopharma industry
- Overview of licensing deal structure
- Directory of licensing deal records covering pharmaceutical and biotechnology
- The leading licensing deals by value
- Most active licensing dealmakers
- The leading licensing partnering resources
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in licensing dealmaking
2.1. Introduction
2.2. Definition of licensing deal
2.3. Trends in licensing deals since 2019
2.3.1. Licensing dealmaking by year, 2019-2024
2.3.2. Licensing dealmaking by phase of development, 2019-2024
2.3.3. Licensing dealmaking by industry sector, 2019-2024
2.3.4. Licensing dealmaking by therapy area, 2019-2024
2.3.5. Licensing dealmaking by technology type, 2019-2024
2.3.6. Licensing dealmaking by most active company, 2019-2024
2.4. Reasons for entering into licensing partnering deals
2.5. The future of licensing deals
Chapter 3 – Overview of licensing deal structure
3.1. Introduction
3.2. Licensing agreement structure
Chapter 4 – Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value
Chapter 5 – Top 25 most active licensing dealmakers
5.1. Introduction
5.2. Top 25 most active licensing dealmakers
Chapter 6 – Licensing deals including contracts directory
6.1. Introduction
6.2. Licensing deals with contracts 2019-2024
Deal directory
Deal directory – licensing dealmaking by companies A-Z
Deal directory – licensing dealmaking by therapy area
Deal directory – licensing dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/r/18u7cl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900